Octrea Indications/Uses

Octreotide is indicated for symptomatic control and reduction growth hormone (GH) and IGF-1 plasma level in patient with acromegaly who are inadequately controlled by surgery or radiotherapy. Octerotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.
Octreotide is indicated for relief of symptoms associated with functional gastro-entero-pancreatic (GEP) endocrine tumors such as: Carcinoid Tumors: Octreotide is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease.
Vasoactive intestinal peptide tumors (VIPomas): Octreotide is indicated for the treatment of profuse watery diarrhea associated with VIP-secreting tumors.
Gastrinoma (Zollinger-Ellison syndrome) usually use in conjunction with proton pump inhibitors.
Insulinomas: Octreotide is indicated for pre-operative control of hypoglycemia and for maintenance therapy.
GRFomas (growth hormone-releasing factor-secreting tumor): Octreotide is not anti-tumor therapy and is not curative in these patients.
It is also indicated for the prevention of complications following pancreatic surgery, and for the emergency management to stop bleeding gastroesophageal varices in patients with cirrhosis, endoscopic sclerotherapy and may be used in treatment of other disorders such as HIV-associated diarrhea, pancreatic endocrine tumors (especially islet cell tumors).